International Journal of STD & AIDS > Volume 20, Supplement 2 > Pp. 12-17

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Geretti, A M PubMed PubMed Citation Social Bookmarking                      What's this?

SUPPLEMENT

Understanding protease inhibitor resistance – aiming for the long term in treatment-experienced patients

A M Geretti MD PhD 

Royal Free Hampstead NHS Trust and UCL Medical School, London, UK

Correspondence to: Dr A M Geretti, Department of Virology, Royal Free Hampstead NHS Trust and University College London Medical School, Pond Street, London NW3 2QG, UK Email: a.geretti{at}medsch.ucl.ac.uk

The prevalence of antiretroviral drug resistance in patients undergoing routine testing while receiving treatment in the UK is about 50%. Most resistance is against nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors, but 25% of patients receiving protease inhibitors (PIs) also have evidence of PI resistance. Although extensive resistance profiles are rare, a proportion of patients present with complex genotypes, which makes treatment selection difficult and vitally important. A resistance profile can be interpreted to provide an indication of the degree of resistance to different drugs and the potential drug options. Factors to bear in mind during treatment selection include phenotypic and genotypic resistance, mutation patterns, numbers and ‘weights’, and the hypersusceptibility and fitness effects of certain mutations. In treatment-experienced patients, physicians should aim for a regimen that combines at least two, preferably three, fully active drugs. In addition to selecting drugs that are predicted to have activity, the relative genetic barrier, cross-resistance potential and support needed to maintain activity in the long term are also key considerations.

Key Words: genotype • HIV • phenotype • protease inhibitor • mutation • resistance • profile • treatment experienced

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?